Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients
Clinical trial NCT03221842 · TERMINATED
Trial details
- NCT number
- NCT03221842
- Sponsor
- CSL Behring
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-06
- Primary completion
- 2021-01-20
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.